Reply to Letter to the Editor: “Anticoagulation in Real-Life Patients with Atrial Fibrillation: Impact of Renal Disease”
暂无分享,去创建一个
Tuncay Güzel | M. Özbek | M. Demir | A. Aktan | Bayram Arslan | Raif Kılıç | F. Ertaş
[1] Tuncay Güzel,et al. Oral Anticoagulant Use and Long-Term Follow-Up Results in Patients with Non-valvular Atrial Fibrillation in Turkey AFTER-2 Study , 2022, Anatolian journal of cardiology.
[2] R. de Caterina,et al. Should We Continue Assessing Glomerular Filtration Rate with the Cockroft–Gault Formula in NOAC-Treated Patients? The Magnitude of the Problem , 2020, Journal of clinical medicine.
[3] T. Potpara,et al. Bleeding in anticoagulated patients with atrial fibrillation: practical considerations. , 2020, Polish archives of internal medicine.
[4] Hugh Calkins,et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. , 2019, Heart rhythm.
[5] A. Camm,et al. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. , 2018, European heart journal.
[6] G. Lip,et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report , 2012, Chest.
[7] G. Lip,et al. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study , 2017, British Medical Journal.
[8] Ulrich Schotten,et al. 2016 ESC Guidelines for the Management of Atrial Fibrillation Developed in Collaboration With EACTS. , 2017, Revista espanola de cardiologia.
[9] P. Kirchhof,et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. , 2016, Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology.
[10] E. Kalaycıoğlu,et al. ReAl-life Multicenter Survey Evaluating Stroke prevention strategies in non-valvular atrial fibrillation (RAMSES study) , 2016, Anatolian journal of cardiology.
[11] Z. Harel,et al. Comparisons between novel oral anticoagulants and vitamin K antagonists in patients with CKD. , 2014, Journal of the American Society of Nephrology : JASN.
[12] E. Antman,et al. Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.
[13] D. Atar,et al. Apixaban versus warfarin in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[14] Jun Zhu,et al. Apixaban in patients with atrial fibrillation. , 2011, The New England journal of medicine.
[15] R. Troughton,et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.
[16] S. Yusuf,et al. Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.
[17] G. Breithardt,et al. Dilemmas in the management of atrial fibrillation in chronic kidney disease. , 2009, Journal of the American Society of Nephrology : JASN.
[18] G. Lip,et al. Antithrombotic therapy for atrial fibrillation , 2002, BMJ : British Medical Journal.